Literature DB >> 669870

Methylergometrine (methylergonovine) concentrations in the human plasma and urine.

R Mäntylä, T Kleimola, J Kanto.   

Abstract

There were no significant differeneces in the radioimmunologically determined plasma concentrations of methylergometrine, nor in its 32-hour cumulative urinary excretion after a sinlge 0.250-mg p.o. dose of Methergin (Sandoz) or Myomergin (Leiras). Peak plasma concentrations were obtained as early as 0.5 hours after the drug administration. Approximately 3% of the 0.250-mg p.o. dose was excreted in the urine during a period of 32 hours. In two subjects, after a single 0.20-mg i.v. injection, the beta phase half-life in the plasma was 1.9 hours. From the ratio of the area under the plasma curve after p.o. and i.v. administration in these two subjects, it was estimated that 64% and 63% of the p.o. dose reached the systemic circulation. No cumulation in the plasma was observed after repeated p.o. doses of 0.125 mg of methylergometrine given thrice daily to the two subjects.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 669870

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Biopharm        ISSN: 0340-0026


  3 in total

Review 1.  Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology.

Authors:  A N de Groot; P W van Dongen; T B Vree; Y A Hekster; J van Roosmalen
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

2.  Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers.

Authors:  J J Ibraheem; L Paalzow; P Tfelt-Hansen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

3.  Distribution of methylergometrine in the breast milk of dogs.

Authors:  R Mäntylä
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1980       Impact factor: 2.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.